In this article for #HighBloodPressureMonth, our Chief Executive Officer, Jon Congleton, discusses the limitations of current medications for high blood pressure control and the need for more targeted therapies.
Mineralys Therapeutics, Inc.’s Post
More Relevant Posts
-
At Mineralys Therapeutics, our purpose is to create more, better days for people dealing with #hypertension and cardio-renal-metabolic disorders. This week, our team came together in Boulder, Colorado, for our annual all-staff meeting. United by this purpose, we delved into the opportunity we have to transform the treatment of hypertension and for a multitude of cardio-renal-metabolic disorders. The summit wasn't just about business. We also dedicated time to giving back to the Boulder community with a volunteer initiative and a refreshing group hike. It was a powerful reminder of the impact our work can have on people. As we move forward, the energy and ideas generated during our time together will propel us through the rest of 2024 and beyond. We are a team united in our commitment to addressing some of the largest unmet medical needs today. Together, we're working tirelessly to create more, better days. #Aldosterone #CardioRenalMetabolic #DrugDiscovery #Leadership #TeamWork #PatientCare
-
-
-
-
-
+1
To view or add a comment, sign in
-
-
Last week we announced the appointment of Alexander M. Gold, MD, to our Board of Directors. Dr. Gold brings over 20 years of experience leading the development, approval, and commercialization of new therapies. $MLYS
Read Our Press Release to Learn More
ir.mineralystx.com
To view or add a comment, sign in
-
There is a link between uncontrolled #hypertension and certain conditions like obesity, where dysregulated aldosterone may be hindering blood pressure control. In these patients, a better-targeted treatment may be the solution. #HighBloodPressureMonth
MedPage Today | Lorundrostat Stands a Chance Against Obesity-Related Hypertension
medpagetoday.com
To view or add a comment, sign in
-
We’re honored to have received the Life Sciences & Healthcare Investment Deal award from Philadelphia Alliance for Capital and Technologies (PACT) at the 2024 PACT Enterprise Awards this past Wednesday. With the Philadelphia region being home to some of the top innovators and leaders across the technology, life sciences and healthcare industries, we couldn’t be more proud to be among this year’s winners. Listen to PACT’S interview with our CEO, Jon Congleton, to learn more. $MLYS #HealthcareInnovation #Hypertension
2024 ENTERPRISE AWARDS
https://www.youtube.com/
To view or add a comment, sign in
-
#Hypertension puts people at a high risk of serious health outcomes, yet ~50% of patients have blood pressure that remains uncontrolled. Read about our novel approach, which was developed to address a key factor – aldosterone. #HighBloodPressureMonth
Cleveland Clinic | Clinical Trial Shows Drug Developed to Treat Uncontrolled Hypertension Significantly Lowers Blood Pressure
newsroom.clevelandclinic.org
To view or add a comment, sign in
-
A new study from researchers at Harvard Medical School looked at a decade’s worth of data from over 10K people who participated in the National Health and Nutrition Examination Survey (NHANES) to determine stages of cardiovascular, kidney, and metabolic (CKM) diseases, which is a group of disorders that are interrelated and can lead to #heartdisease if left unchecked. They found that 90% of American adults met the criteria for early, middle or late stages of CKM syndrome. Additionally, 15% were categorized as having advanced disease – and given this number remained consistent, the researchers hypothesized that the #obesity epidemic may be playing a part. #HighBloodPressureMonth
JAMA: Cardiovascular-Kidney-Metabolic Syndrome Stages in US Adults
jamanetwork.com
To view or add a comment, sign in
-
Last month we were honored with Life Sciences Pennsylvania's “2023 Deal of the Year” award for our successful IPO in the midst of a difficult year for the #biotech sector. Listen to the podcast episode with Jon Congleton, President and CEO, to learn more: https://lnkd.in/ePBHA4MF #MLYS
To view or add a comment, sign in
-
-
Resistant hypertension is defined by high #bloodpressure that persists despite taking ≥3 medications, and among the possible causes is dysregulated aldosterone. Read about this hormone's role, and how we're working to address it. #HighBloodPressureMonth
Healio | Aldosterone: The hidden hormone linking hypertension and obesity, and a potential target
healio.com
To view or add a comment, sign in
-
Today we reported financial results for the quarter ending March 31, 2024. Read our press release for highlights, including anticipated readouts from our pivotal trials for lorundrostat in #hypertension, and proof-of-concept in hypertension and #CKD. #MLYS
Read Our Press Release to Learn More
ir.mineralystx.com
To view or add a comment, sign in